Form 4: Pacific Biosciences Director Randall Livingston Granted 65,000 Stock Options

Pacific Biosciences of California, Inc. director Randall S. Livingston was granted 65,000 stock options with an exercise price of $1.03, vesting monthly over one year.

Summary

• Randall S. Livingston, a Director of Pacific Biosciences of California, Inc. (PACB), was granted 65,000 stock options on June 4, 2025.
• The options have an exercise price of $1.03 per share.
• These options will vest monthly over a one-year period, with the first portion becoming exercisable on July 4, 2025.
• The vesting is contingent upon Mr. Livingston's continued service as a director through the applicable vesting dates.
• The options have an expiration date of June 4, 2035.
• Following this transaction, Mr. Livingston beneficially owns 65,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event for corporate governance and alignment of interests, indicating continued commitment. It's a standard compensation practice.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule encourages continued service and commitment from the director.

Negatives

• The issuance of new stock options could lead to potential future dilution for existing shareholders if exercised, though this is a standard form of equity compensation.

Risks

• The value of the stock options is dependent on the future stock price of Pacific Biosciences of California, Inc., meaning the options could become worthless if the stock price does not exceed the exercise price.
• Vesting is contingent on continued service, so the director would forfeit unvested options if they cease to be a director.

Future Outlook

The vesting schedule indicates a future commitment from the director to the company for at least one year to fully realize the benefit of the options.

Industry Context

This is a standard equity compensation practice for directors in publicly traded companies, particularly in the biotechnology sector, to attract and retain talent and align interests.

Comparison to Industry Standards

• Granting stock options to directors is a common practice across industries, including biotechnology, as a form of long-term incentive compensation.
• The vesting schedule (monthly over one year) is a typical approach to ensure continued service and alignment.
• The exercise price being set at a specific value (e.g., $1.03) is common for options, often related to the stock price at the time of grant.

Corporate Governance

Related Party Transactions

• The grant of stock options to a director can be considered a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also improved alignment of director's interests with shareholder value creation.

Next Steps

• Continued service of Randall S. Livingston as a director to ensure full vesting of options.
• Monthly vesting of the 65,000 stock options over one year.
• Potential future exercise of options by Randall S. Livingston, subject to vesting and market conditions.

Key Dates

Keywords

Pacific Biosciences, PACB, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Randall Livingston, Biotechnology, Genomics